Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells

Immunology and Cell Biology

Volumn 91, Issue 1, 2013, Pages 32-39

  Jacobs, Sandra A ^a   Roobrouck, Valerie D ^a   Verfaillie, Catherine M ^a   Van Gool, Stefaan W ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

immunomodulation; mesenchymal stem cells; multipotent adult progenitor cells; phenotype

Indexed keywords

ADAPALENE; CD146 ANTIGEN; GANGLIOSIDE GD2; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN SH3; PROTEIN TYROSINE PHOSPHATASE SHP; STAGE SPECIFIC EMBRYO ANTIGEN 4; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX17; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX7; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; APOPTOSIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; DENDRITIC CELL; EMBRYONIC STEM CELL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPOTENT STEM CELL; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SENESCENCE;

ADULT STEM CELLS; AGING; BONE MARROW CELLS; CELL DIFFERENTIATION; HUMANS; MESENCHYMAL STROMAL CELLS; REGENERATIVE MEDICINE;

EID: 84872149212     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.64     Document Type: Review

References (100)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147. (Pubitemid 29282067)
2. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-634. (Pubitemid 39014578)
3. De Bari C, Dell'Accio F, Luyten FP. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum 2001; 44: 85-95. (Pubitemid 32113122)
4. In't Anker PS, Scherjon SA, Kleijburg-van der KC, Noort WA, Claas FH, Willemze R et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003; 102: 1548-1549. (Pubitemid 36988070)
5. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-4295. (Pubitemid 35471185)
6. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317. (Pubitemid 44269669)
7. Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 2007; 109: 1743-1751. (Pubitemid 46239610)
8. Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003; 116: 1827-1835. (Pubitemid 36582169)
9. Haynesworth SE, Baber MA, Caplan AI. Cell surface antigens on human marrowderived mesenchymal cells are detected by monoclonal antibodies. Bone 1992; 13: 69-80.
10. Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs. Blood 2007; 109: 4245-4248. (Pubitemid 46743389)
11. Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers GL. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002; 30: 783-791. (Pubitemid 34835685)
12. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I et al. Selfrenewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 324-336. (Pubitemid 47592917)
13. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-313.
14. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49. (Pubitemid 34742565)
15. Ulloa-Montoya F, Kidder BL, Pauwelyn KA, Chase LG, Luttun A, Crabbe A et al. Comparative transcriptome analysis of embryonic and adult stem cells with extended and limited differentiation capacity. Genome Biol 2007; 8: R163.
16. Subramanian K, Geraerts M, Pauwelyn KA, Park Y, Owens DJ, Muijtjens M et al. Isolation procedure and characterization of multipotent adult progenitor cells from rat bone marrow. Methods Mol Biol 2010; 636: 55-78.
17. Lo Nigro A, Geraerts M, Notelaers T, Roobrouck VD, Muijtjens M, Eggermont K et al. MAPC culture conditions support the derivation of cells with nascent hypoblast features from bone marrow and blastocysts. J Mol Cell Biol (e-pub ahead of print 9 August 2012).
18. Kunath T, Arnaud D, Uy GD, Okamoto I, Chureau C, Yamanaka Y et al. Imprinted X-inactivation in extra-embryonic endoderm cell lines from mouse blastocysts. Development 2005; 132: 1649-1661. (Pubitemid 40575865)
19. Debeb BG, Galat V, Epple-Farmer J, Innaccone S, Woodward WA et al. Isolation of Oct4-expressing extraembryonic endoderm precursor cell lines. PLoS One 2009; 4: E7216.
20. Ross JJ, Hong Z, Willenbring B, Zeng L, Isenberg B, Lee EH et al. Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. J Clin Invest 2006; 116: 3139-3149. (Pubitemid 44878628)
21. Roelandt P, Pauwelyn KA, Sancho-Bru P, Subramanian K, Bose B, Ordovas L et al. Human embryonic and rat adult stem cells with primitive endoderm-like phenotype can be fated to definitive endoderm, and finally hepatocyte-like cells. PLoS One 2010; 5: E12101.
22. Maes C, Coenegrachts L, Stockmans I, Daci E, Luttun A, Petryk A et al. Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair. J Clin Invest 2006; 116: 1230-1242.
23. Jiang Y, Henderson D, Blackstad M, Chen A, Miller RF, Verfaillie CM. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proc Natl Acad Sci USA 2003; 100(Suppl 1): 11854-11860. (Pubitemid 37205895)
24. Aranguren XL, Luttun A, Clavel C, Moreno C, Abizanda G, Barajas MA et al. In vitro and in vivo arterial differentiation of human multipotent adult progenitor cells. Blood 2007; 109: 2634-2642. (Pubitemid 46425914)
25. Muguruma Y, Reyes M, Nakamura Y, Sato T, Matsuzawa H, Miyatake H et al. In vivo and in vitro differentiation of myocytes from human bone marrow-derived multipotent progenitor cells. Exp Hematol 2003; 31: 1323-1330. (Pubitemid 37510039)
26. Qi H, Aguiar DJ, Williams SM, La PA, Pan W, Verfaillie CM. Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells. Proc Natl Acad Sci USA 2003; 100: 3305-3310. (Pubitemid 36356578)
27. Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002; 109: 1291-1302. (Pubitemid 34546893)
28. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109: 337-346. (Pubitemid 34141807)
29. Aranguren XL, McCue JD, Hendrickx B, Zhu XH, Du F, Chen E et al. Multipotent adult progenitor cells sustain function of ischemic limbs in mice. J Clin Invest 2008; 118: 505-514. (Pubitemid 351206541)
30. Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Grippa S, Sohni A et al. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 2011; 29: 871-882.
31. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 1996; 153: 47-83. (Pubitemid 27010763)
32. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW et al. T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47-57. (Pubitemid 40576763)
33. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20. (Pubitemid 38019084)
34. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003; 75: 389-397. (Pubitemid 36222968)
35. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
36. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843. (Pubitemid 34534559)
37. Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004; 60: 307-315. (Pubitemid 39141263)
38. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729. (Pubitemid 36857965)
39. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 2004; 103: 4619-4621. (Pubitemid 38745993)
40. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604. (Pubitemid 43090404)
41. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33-41. (Pubitemid 40380651)
42. Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 2005; 338: 20-24. (Pubitemid 41540532)
43. Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, Rouas-Freiss N et al. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009; 87: S62-S66.
44. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 + T-cell subsets expressing a regulatory/ suppressive phenotype. Haematologica 2005; 90: 516-525. (Pubitemid 40592895)
45. Sioud M, Mobergslien A, Boudabous A, Floisand Y. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol 2011; 38: 385-390.
46. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827. (Pubitemid 40446275)
47. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372. (Pubitemid 43053565)
48. Traggiai E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L et al. Bone marrowderived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26: 562-569. (Pubitemid 351413617)
49. Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 84-90. (Pubitemid 350192306)
50. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol 2002; 3: 6-8. (Pubitemid 34065607)
51. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-1213. (Pubitemid 37339646)
52. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-1490. (Pubitemid 43242385)
53. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333. (Pubitemid 351213419)
54. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
55. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 +CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222.
56. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087. (Pubitemid 44200965)
57. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583.
58. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126. (Pubitemid 40656164)
59. Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, Van't Hof W, Deans R et al. Human multipotent adult progenitor cells are non-immunogenic and exert potent immunomodulatory effects on alloreactive T cell responses. Cell Transplant (e-pub ahead of print, 1 october 2012). 60 Noel D, Djouad F, Jorgense C. Regenerative medicine through mesenchymal stem cells for bone and cartilage repair. Curr Opin Investig Drugs 2002; 3: 1000-1004.
60. Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 2008; 111: 4551-4558.
61. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-1084. (Pubitemid 44128350)
62. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54: 2277-2286.
63. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109: 1543-1549. (Pubitemid 38420184)
64. Tang Y, Yasuhara T, Hara K, Matsukawa N, Maki M, Yu G et al. Transplantation of bone marrow-derived stem cells: A promising therapy for stroke. Cell Transplant 2007; 16: 159-169. (Pubitemid 46668790)
65. Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 2009; 11: 503-515.
66. Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L et al. Homing of in vitro expanded Stro-1-or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 2004; 103: 3313-3319. (Pubitemid 38525658)
67. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrowderived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000; 9: 841-848. (Pubitemid 32110282)
68. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-316. (Pubitemid 30056419)
69. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
70. Lee ST, Jang JH, Cheong JW, Kim JS, Maemg HY, Hahn JS et al. Treatment of highrisk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002; 118: 1128-1131. (Pubitemid 35025980)
71. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21: 1733-1738. (Pubitemid 47086763)
72. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764-2767. (Pubitemid 47523204)
73. Fouillard L, Bensidhoum M, Bories D, Bonte H, Lopez M, Moseley AM et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia 2003; 17: 474-476. (Pubitemid 36266932)
74. Fouillard L, Chapel A, Bories D, Bouchet S, Costa JM, Rouard H et al. Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. Leukemia 2007; 21: 568-570.
75. Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: A pilot study. Stem Cells Dev 2009; 18: 1247-1252.
76. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579-1586. (Pubitemid 351626841)
77. Newman RE, Yoo D, LeRoux MA, nilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009; 8: 110-123.
78. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia 2008; 22: 593-599. (Pubitemid 351386730)
79. Liu K, Chen Y, Zeng Y, Xu L, Liu D, Chen H et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells Dev 2011; 20: 1679-1685.
80. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441. (Pubitemid 38586721)
81. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397. (Pubitemid 43847148)
82. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 25-32. (Pubitemid 350199635)
83. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43: 245-251.
84. Fang B, Song Y, Lin Q, Zhang Y, Cao Y, Zhao RC et al. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 2007; 11: 814-817. (Pubitemid 47512333)
85. Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS et al. Improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: Results of a randomized, placebocontrolled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010; 16: S169-S170.
86. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 804-811.
87. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011; 17: 534-541.
88. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versushost disease: Clinical report. Biol Blood Marrow Transplant 2010; 16: 403-412.
89. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010; 45: 1732-1740.
90. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011; 10: 649-656.
91. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60: 788-798.
92. Tyndall A, van Laar JM. Stem cells in the treatment of inflammatory arthritis. Best Pract Res Clin Rheumatol 2010; 24: 565-574.
93. Boozer S, Lehman N, Lakshmipathy U, Love B, Raber A, Maitra A et al. Global characterization and genomic stability of human multistem, a multipotent adult progenitor cell. J Stem Cells 2009; 4: 17-28.
94. Kovacsovics-Bankowski M, Mauch K, Raber A, Streeter PR, Deans RJ, Maziarz RT et al. Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 2008; 10: 730-742.
95. Penn MS, Ellis S, Gandhi S, Greenbaum A, Hodes Z, Mendelsohn FO et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: Phase I clinical study. Circ Res 2012; 110: 304-311.
96. Lehman N, Cutrone R, Raber A, Perry R, van't Hof W, Deans R et al. Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy 2012; 14: 994-1004.
97. Maziarz. poster abstract 165 American Society for Bone Marrow Transplantation Tandem meeting. San Diego, 2012.
98. Buron F, Perrin H, Malcus C, Hequet O, Thaunat O, Kholopp-Sarda MN et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: An in vitro study using human cells. Transplant Proc 2009; 41: 3347-3352.
99. Eggenhofer E, Steinmann JF, Renner P, Slowik P, Piso P, Geissler EK et al. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol 2011; 24: 157-163.
100. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81: 1589-1595. (Pubitemid 43890897)